Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

CA14161Y2006
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00M0GNP68
CRDL
Cardiol Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Cardiol Therapeutics Inc
ISIN
CA14161Y2006
TICKER
CRDL
MIC
XTSX
REUTERS
CRDL.TO
BLOOMBERG
CRDL CN
Thu, 29.05.2025       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (t...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.05.2025       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Sharehold...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.04.2025       Cardiol Therapeutics
CA14161Y2006

Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experienceToronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapi...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.04.2025       Cardiol Therapeutics
CA14161Y2006

Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 23.04.2025 / 15:24 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to co......
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.04.2025       Cardiol Therapeutics
CA14161Y2006

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.D...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 01.04.2025       Cardiol Therapeutics
CA14161Y2006

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trialCompleted patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, w...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.03.2025       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.02.2025       Cardiol Therapeutics
CA14161Y2006

Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failureToronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences compa...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.02.2025       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will pr...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.11.2024       Cardiol Therapeutics
CA14161Y2006

Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to......
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 18.11.2024       Cardiol Therapeutics
CA14161Y2006

Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trialsToronto, Ontario--(Newsfile Corp. - November 18...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.10.2024       Cardiol Therapeutics
CA14161Y2006

Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 28.10.2024 / 15:45 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to......
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.10.2024       Cardiol Therapeutics
CA14161Y2006

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program.Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Compa...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.10.2024       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.10.2024       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfu...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.10.2024       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its pre...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.10.2024       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.09.2024       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced it has achieved the...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.09.2024       Cardiol Therapeutics
CA14161Y2006

Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focuse...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.06.2024       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual gen...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 25.06.2024       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annu...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.06.2024       Cardiol Therapeutics
CA14161Y2006

Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Cardiol Therapeutics Inc Company Name: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Reason for the research: Update Recommendation: Buy from: 14.06.2024 Target price: USD8.50 Target price on sight of: 12 months......
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.06.2024       Cardiol Therapeutics
CA14161Y2006

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyToronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ:...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.05.2024       Cardiol Therapeutics
CA14161Y2006

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart FailureARCHER trial has now exceeded 85% of target patient e...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.04.2024       Cardiol Therapeutics
CA14161Y2006

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditisExceeded 50% enrollment in the Phase II ARCHER t...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.02.2024       Cardiol Therapeutics
CA14161Y2006

Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Cardiol Therapeutics Inc Company Name: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Reason for the research: Update Recommendation: Buy from: 27.02.2024 Target price: USD 3.60 Target price on sight of: 12 month......
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 21.02.2024       Cardiol Therapeutics
CA14161Y2006

Topline Results Expected in Q2 2024This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.02.2024       Cardiol Therapeutics
CA14161Y2006

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research a...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 24.01.2024       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that it received notic...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.01.2024       Cardiol Therapeutics
CA14161Y2006

Original-Research: Cardiol Therapeutics Inc - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Cardiol Therapeutics Inc Unternehmen: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Anlass der Studie: Update Empfehlung: Buy seit: 19.01.2024 Kursziel: USD 3.60 Kursziel auf Sicht von: 12 months Letzte Ratingänderu......
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.01.2024       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it has exce...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.12.2023       Cardiol Therapeutics
CA14161Y2006

MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024Toronto, Ontario--(Newsfile Corp. - December 5, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical developmen...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.11.2023       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today that study results de...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.11.2023       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it has exc...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.10.2023       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - October 20, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that on October 19, 2023, it...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.10.2023       Cardiol Therapeutics
CA14161Y2006

Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac Inflammation and RemodellingData Presented at the Heart Failure Society of America Annual Scientific Meeting 2023 Toronto, Ontario--(Newsfile Corp. - October 10, 2023) - Cardiol Therapeutics I...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.09.2023       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - September 26, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol'...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.09.2023       Cardiol Therapeutics
CA14161Y2006

Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center, International, Double-blind, Placebo-controlled Trial Randomizing 100 PatientsToronto, Ontario--(Newsfile Corp. - September 19, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.08.2023       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - August 9, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol's Pr...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.08.2023       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - August 8, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that it received notice...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.06.2023       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual Ge...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.06.2023       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 27, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today is pleased to announce that the Co...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.03.2023       Cardiol Therapeutics
CA14161Y2006

Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shortness of breath and fatigue, resulting in markedly reduced quality of life, emergency department visits,...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.03.2023       Cardiol Therapeutics
CA14161Y2006

Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart TissueData Presented at The American College of Cardiology's 72nd Annual Scientific Session Together with the World Congress of Cardiology Oakville, Ontario--(Newsfile Corp. - March 7, 2023) -...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.01.2023       Cardiol Therapeutics
CA14161Y2006

The Cleveland Clinic Recruits First Participant in the Multi-center U.S. StudyOakville, Ontario--(Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic thera...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.12.2022       Cardiol Therapeutics
CA14161Y2006

The Cleveland Clinic and the Mayo Clinic Study Sites have been Initiated and are Eligible to Recruit ParticipantsInitiation of Additional U.S. Cardiovascular Research Centers is Planned for Q1, 2023 Oakville, Ontario--(Newsfile Corp. - December 12, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.11.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - November 14, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced that on November 14, 2022...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 07.11.2022       Cardiol Therapeutics
CA14161Y2006

Results Demonstrate Significant Reduction in Pericardial Effusion and Thickness and Significant Suppression of Key Inflammatory Markers IL-1β and IL-6Data Presented at The American Heart Association Scientific Sessions 2022 Oakville, Ontario--(Newsfile Corp. - November 7, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.10.2022       Cardiol Therapeutics
CA14161Y2006

Discontinues LANCER Trial due to Lack of Eligible Patients for RecruitmentCash Runway Now Extends into 2026Oakville, Ontario--(Newsfile Corp. - October 25, 2022) -  Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-i...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.10.2022       Cardiol Therapeutics
CA14161Y2006

Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022Oakville, Ontario--(Newsfile Corp. - October 3, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflamm...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink